Monobenzyl Ether of Hydroquinone in Depigmentation of Vitiligo.

Monobenzyl Ether of Hydroquinone (MBEH) 20% and 40% Cream in Depigmentation of Vitiligo Patients: Randomized controlled trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR201808699550182

Enrollment

Registered

2018-08-31

Start date

2016-11-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases

Interventions

Monobenzyl ether of hydroquinone 20 percent

Monobenzyl ether of hydroquinone 40 percent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Age above 12 years, both sexes. ? Vitiligo patients with >50% body surface area (BSA) involvement retaining few small areas of normal color on face and/or hands. ? Vitiligo patients with <50% BSA involvement who are refractory to treatment and aspire at improving aesthetically on face and/or hands.

Exclusion criteria

Exclusion criteria: ? Segmental Vitiligo. ? Vitiligo responsive to treatment. ? Pregnant or breastfeeding women. ? Known allergy to MBEH. ? Hepatic or renal diseases. ? Concomitant oral corticosteroid or immunosuppressive therapy.

Design outcomes

Primary

Measure	Time frame
compare two concentrations of MBEH, 20% and 40% regarding efficacy, tolerability and side effects	—

Secondary

Measure	Time frame
observe in detail the changes that pigmented skin in vitiligo patients undergoes until complete depigmentation ;the effect of treatment on patients QOL	—

Countries

Egypt

Contacts

Public ContactDina Saadi

Lecturer Cairo university

dina.saadi@hotmail.com+201222442771

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026